Making A Difference for Your AD Patients: Patient-Centric Strategies to Improve Their Care - Pediatric Patient - POCN
:Home>>Making A Difference for Your AD Patients: Patient-Centric Strategies to Improve Their Care – Pediatric Patient

Making A Difference for Your AD Patients: Patient-Centric Strategies to Improve Their Care – Pediatric Patient

Dermatology | January 31, 2022

Launch Date:

January 31, 2022

Expiration Date:

January 1, 2023

primary audience:

Allergists, Dermatologists, Immunologists, Nurse practitioners, Pediatric specialists (md/dos), Physician assistants

Relevant Terms:

Atopic dermatitis, Biologic therapy, Shared decision-making

course faculty

Robert Sidbury, MD, MPH

Robert Sidbury MD, MPH got his undergraduate and medical degrees from Duke University, and his Masters in Public Health from Harvard.  He did his internship and residency at UCSF and the Oregon Health and Science University, and completed fellowships at Northwestern University  and Harvard.   He has held faculty positions at Harvard Medical School and the University of Washington School of Medicine where he is currently Professor in the Department of Pediatrics and chief of the division of dermatology.  His clinical and research interests include atopic dermatitis, vascular tumors of infancy, vitamin D, and pediatric health services.   He spends most of his time outside of work playing with his thirteen year old daughter Claire. 

Steven R. Feldman, MD, PhD

Steven Feldman received his MD and PhD degrees from Duke University and completed dermatology residency at the University of North Carolina at Chapel Hill and dermatopathology residency at the Medical University of South Carolina.  He is Professor of Dermatology, Pathology, Social Sciences & Health Policy and Molecular Medicine & Translational Science at the Wake Forest School of Medicine.  He leads the Center for Dermatology Research, a health services research center whose mission is to improve the care of patients with skin disease. Dr. Feldman served on the American Academy of Dermatology’s atopic dermatitis guidelines committee.  He has done ground breaking work on patients’ adherence to their medication treatment regimens, the latter leading to the Wake Forest spin off company Causa Research.  Feldman’s clinical work led him to an interest in patient satisfaction.  Feldman created the doctor rating/patient satisfaction website.  He has given invited lectures to dermatology groups and organizations around the world including the Pan Arab Dermatology Meeting held in Riyadh, Saudi Arabia, the Iranian Dermatology Society meeting in Tehran, Iran, and the Pan Asian Dermatology Meeting held in Seoul, Korea.  Feldman’s experiences in medicine have led him to try to see how others perceive things, leading to his book Compartments and his recent novella Bent Toward Justice.  Feldman serves on the board of the North Carolina-based Coalition for Peace with Justice.  His research has been published in over 1,000 Medline-reference articles. Feldman also serves as the editor of the Journal of Dermatological Treatment and the Journal of Dermatology and Dermatological Surgery and as chief medical editor of The Dermatologist.

learning objectives
1. Describe optimal shared decision-making strategies to effectively engage patients/caregivers
2. Integrate patient/caregiver preferences into guideline-recommended treatment decisions
3. Tailor atopic dermatitis therapy for patients whose symptoms are poorly managed by current treatment
course information
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.

Horizon CME designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 0.75 AMA PRA Category 1 Credits™. A statement of credit will be available to print from your user history page.


Horizon CME requires all planners, faculty, and other contributors to disclose any financial relationships with an ACCME defined ineligible company within the past 24 months and Horizon CME has resolved any conflicts prior to this educational activity..

Faculty Disclosures

Robert Sidbury, MD, MPH

Advisory Boards: Leo Pharma

Contracted Research: Regeneron, Galderma, Pfizer, and Castle.


Steven Feldman, MD, PhD

Consultant: Abbvie, Janssen, Alvotech, vTv, BMS, Samsung, Pfizer, Boehringer, Dermavant, Arcutis, Novartis, UCB, Helsinn, Sun, Almirall, Leo, Mylan, Forte, Arena, Biocon, Accordant, Argenx, and Sanofi.

Speaker: Lilly, Abbvie, Janssen, Alvotech, Amgen, Sun, Sanofi, and Regeneron.

Research Funding: Lilly Abbvie, janssen, Pfizer, UCB, Almirall, and Galderma.


Planner Disclosures

Those involved in the planning of this activity disclosed no financial relationships with an ACCME defined ineligible company within the past 24 months.


Other Contributor Disclosures

All other non-faculty contributors and others involved in the planning, development and editing/review of the content disclosed no financial relationships with an ACCME defined ineligible company within the past 24 months.


Disclosure of Unlabeled Use

Horizon CME requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.



This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.


Statement of Independence

Per ACCME, AMA and FDA regulations, it is understood that commercial supporters will have no influence on the content of the activity.  Horizon CME will ensure an unbiased presentation and provide full disclosure of relationships between Horizon CME and all commercial supporters and any significant financial interest or other relationship between faculty and manufacturers of commercial products discussed in the activities.  It is understood that commercial support funding of this activity is not in any way conditioned upon any present or future business relationship. 


Commercial Support
This activity is supported by an independent education grant from Sanofi Genzyme and Regeneron Pharmaceuticals.


Copyright © 2022 by Horizon CME.  All rights reserved.  No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from Horizon CME.


Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6+ for Mac OSX 10.7 and above

For video playback, install the latest version of Flash or Quicktime.

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above


Go to Top